David Brown of The Washington Post reports that manufacturing deficiencies at the plants of a major overseas drug maker, Ranbaxy Laboratories, have prompted the Food and Drug Administration to halt imports from the company. FDA officials noted that while the manufacturing violations that triggered the import stoppage were serious, the risk to American consumers was virtually nonexistent. The affected company is the largest drug maker in India and one of the largest producers of generic drugs in the world.
As reported in the Post:
Douglas Throckmorton, a physician with the FDA’s Center for Drug Evaluation and Research, said there was “no evidence of harm to consumers” from drugs made at the Dewas and Paonta Sahib plants, both in India. He called the import ban “a preventive action.” FDA officials said numerous tests of the drugs have found they are not contaminated, sub-potent or unsafe and urged patients taking the drugs not to stop. The drugs on the list include numerous antibiotics and antivirals, as well as medicines for high cholesterol, diabetes, high blood pressure, seasonal allergies and acne.
You can read more HERE.
For more information on our pharamceutical litigation, click HERE.
If you believe you have been injured from taking a prescription drug, including Chantix, Digitek, Byetta or Trasylol, please contact Ed Wallis today at (901) 527-2125, or send Ed an e-mail by clicking HERE.
